ELP-004 TRPC Channel Inhibition for Arthritis Bone Erosion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory arthritis, particularly rheumatoid arthritis, are inadequate in addressing bone erosion and often come with severe side effects, as there is no small molecule drug specifically targeting arthritis-induced bone erosion effectively.
Innovation Solution
The compound N-(3,4-dichlorophenyl)-N-methylpropanamide (ELP-004) targets transient receptor potential channels (TRPC) to restore the balance of osteoclast to osteoblast activity, thereby controlling or reducing arthritis-induced bone erosion, administered orally in a pharmaceutically acceptable composition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for inflammatory arthritis are used, then arthritis symptoms can be managed, but bone erosion continues and severe side effects occur
Solution Approach 1:
The patent extracts and isolates the specific harmful mechanism (osteoclast-mediated bone erosion) from the broader arthritis pathology, then targets it selectively with ELP-004. This allows treatment of bone erosion without affecting other arthritis symptoms, resolving the contradiction by addressing only the harmful bone erosion pathway while leaving other processes intact.
Solution Approach 2:
The patent changes the therapeutic parameter from general anti-inflammatory action to specific ion channel blockade. By targeting TRPC channels with ELP-004, the treatment achieves selective inhibition of osteoclast function, fundamentally changing the approach from broad-spectrum anti-inflammatory therapy to precision-targeted bone protection.
2Adaptability or versatility
If small molecule drugs are developed to target bone erosion, then treatment specificity improves, but no such drug has been successfully created yet
Solution Approach 1:
The patent uses TRPC ion channels as molecular intermediaries to translate the macroscopic goal of preventing bone erosion into a microscopic target for small molecule therapy. ELP-004 acts as the intermediary compound that blocks these channels, providing the missing link between the need for specific bone erosion treatment and the availability of small molecule drugs.
3Reliability
If osteoclast activity is suppressed to prevent bone erosion, then bone protection improves, but osteoblast activity may also be affected disrupting bone balance
Solution Approach 1:
The patent applies local quality by targeting osteoclasts specifically through their unique TRPC channel dependency, while leaving osteoblasts unaffected. The selective blockade of TRPC channels in osteoclasts allows suppression of bone resorption without interfering with bone formation, maintaining the critical balance between osteoclast and osteoblast activities.
Data Source
AI summary
A method of restoring the balance of osteoclast to osteoblast activity in a patient having rheumatoid arthritis comprising administering to a patient a therapeutically effective amount of the compound N-(3,4-dichlorophenyl)-N-methylpropanamide is provided. A method for treating arthritis-induced bone erosion in a patient comprising administering to a patient a therapeutically effective amount of the compound N-(3,4-dichlorophenyl)-N-methylpropanamide is provided. The compound N-(3,4-dichlorophenyl)-N-methylpropanamide is administered in a pharmaceutically acceptable composition to said patient. A mode of action of N-(3,4-dichlorophenyl)-N-methyl propanamide comprising targeting transient receptor potential channels is provided.